Hepatitis C in Renal Transplant Recipients | NCT02108301 | Trialant

Hepatitis C in Renal Transplant Recipients | NCT02108301 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
tacrolimus-cyclosporine A	Experimental	conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients	Drug: tacrolimus-cyclosporine A

Interventions

Name	Type	Description	Arm Group Labels	Other Names
tacrolimus-cyclosporine A	Drug	conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients	tacrolimus-cyclosporine A

Outcomes Module

Secondary Outcomes

Measure	Description	Time Frame
change in oral glucose insulin sensitivity (OGIS) index at 12 weeks		one day before and 12 weeks after the conversion
change in serum hepcidin levels at 12 weeks		one day before and 12 weeks after the conversion

Contacts/Locations Module

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
26735686	Derived	Handisurya A, Kerscher C, Tura A, Herkner H, Payer BA, Mandorfer M, Werzowa J, Winnicki W, Reiberger T, Kautzky-Willer A, Pacini G, Saemann M, Schmidt A. Conversion from Tacrolimus to Cyclosporine A Improves Glucose Tolerance in HCV-Positive Renal Transplant Recipients. PLoS One. 2016 Jan 6;11(1):e0145319. doi: 10.1371/journal.pone.0145319. eCollection 2016.